Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis.

Abstract

In the atypical smooth muscle cells that are characteristic of lymphangioleiomyomatosis (LAM), there are estrogen and progesterone receptors. Therefore, anti-hormonal therapy, despite having produced controversial results, can be considered a treatment option. The objective of this retrospective study was to evaluate hormonal and spirometric data for nine women with LAM after one year of treatment with goserelin. The mean increase in FEV1 and FVC was 80 mL and 130 mL, respectively. There was effective blockage of the hormonal axis. It is still not possible to exclude a potential beneficial effect of the use of gonadotropin-releasing hormone analogues in LAM patients, which underscores the need for randomized trials.

• Authors: Bruno Guedes Baldi, Pedro Medeiros Junior, Suzana Pinheiro Pimenta, Roberto Iglesias Lopes, Ronaldo Adib Kairalla, Carlos Roberto Ribeiro Carvalho
• Journal: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (J Bras Pneumol) 2011 May-Jun Vol. 37 Issue 3 Pg. 375-9 ISSN: 1806-3756 [Electronic] Brazil
• PMID: 21755194 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Hormones
• Goserelin

Topics

• Adult
• Antineoplastic Agents, Hormonal (therapeutic use)
• Female
• Goserelin (therapeutic use)
• Hormones (metabolism)
• Humans
• Lymphangioleiomyomatosis (drug therapy, physiopathology)
• Middle Aged
• Retrospective Studies
• Statistics, Nonparametric
• Vital Capacity (drug effects)
• Young Adult